Substance
CANAGLIFLOZIN
Global reference: every product and company linked to this substance.
- cas: 928672-86-0
- ncit: C91018
- pubchem_cid: 24997615
- rxnorm: 1373458
- unii: 0SAC974Z85
CANAGLIFLOZIN [USAN] · Canagliflozin hemihydrate [WHO-DD] · CANAGLIFLOZIN HYDRATE [JAN] · INVOKAMET COMPONENT CANAGLIFLOZIN · INVOKANA · JNJ-24831754-ZAE · JNJ-28431754-AAA
Revenue by product (2)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| JOHNSON & JOHNSON COMMON STOCK | INVOKAMET | Q4 2022 | $91.0M* |
| JOHNSON & JOHNSON COMMON STOCK | INVOKANA | Q4 2022 | $91.0M* |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (4)
- CANAGLIFLOZIN · TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DEPOSITARY SHARES
- INVOKAMET · JOHNSON & JOHNSON COMMON STOCK
- INVOKAMET XR · JOHNSON & JOHNSON COMMON STOCK
- INVOKANA · JOHNSON & JOHNSON COMMON STOCK